Epizyme gains on latest tazemetostat readout in NHL
By Jaime De Leon | Jun 14, 2017 | 10:43 PM GMT
Epizyme Inc. (NASDAQ:EPZM) gained $1.20 (11%) to $12.35 on Wednesday as investors digested updated results from a Phase II trial of tazemetostat (EPZ-6438) in patients with relapsed or refractory diffuse large
Read the full 311 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury